Name: Maulik Nanavaty
New title: CEO, Anumana
Previous title: senior vice president and president of neuromodulation, Boston Scientific
Anumana has identified Maulik Nanavaty to lead the company through a key period in which it will start to deploy and commercialize its ECG-AI technology.
Massachusetts-based Anumana, which was founded by nference and Mayo Clinic, is developing algorithms for analyzing cardiovascular data. The Food and Drug Administration recently granted 510(k) clearance to an algorithm developed by the company to detect low-ejection fraction using data from a routine 12-lead electrocardiogram.
Having secured the clearance, Murali Aravamudan, co-founder of Anumana, has transitioned to the executive chairman position, freeing up the CEO post. Nanavaty has taken up the job after spending 18 years at Boston Scientific, where he held senior roles in interventional cardiology and neuromodulation. Aravamudan sees the experience as a good fit for Anumana.
“Maulik’s decades of experience developing and bringing to market innovative medical products globally is exactly what is needed to build Anumana into a best-in-class multimodal cardiovascular AI enterprise,” the executive chairman said in a statement.
Nanavaty and Aravamudan will work together to establish the algorithm to detect low-ejection fraction as part of the process for assessing patients at risk of heart failure, while also advancing a pipeline that features three more algorithms with FDA breakthrough designation.
Aravamudan will continue as CEO of nference, one of the founders of Anumana. Nanavaty, who spent 16 years at Baxter early in his career, is joining nference as president of ventures.